Biomarkers /
IDH2
Overview
IDH2 (isocitrate dehydrogenase 2 (NADP+), mitochondrial), encodes for the isocitrate dehydrogenase [NADP], mitochondrial protein, an epigenetic modifier. IDH2 is frequently mutated in glioma and acute myeloid leukemia (PMID: 23071358).
IDH2 is altered in 1.39% of all cancers with acute myeloid leukemia, breast invasive ductal carcinoma, colon adenocarcinoma, lung adenocarcinoma, and oligodendroglioma having the greatest prevalence of alterations [3].
The most common alterations in IDH2 are IDH2 Mutation (1.14%), IDH2 Exon 4 Mutation (0.79%), IDH2 Codon 140 Missense (0.48%), IDH2 R140Q (0.52%), and IDH2 Codon 172 Missense (0.32%) [3].
Biomarker-Directed Therapies
Clinical Trials
Significance of IDH2 in Diseases
References
1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.